WO2012019053A3 - Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 - Google Patents

Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 Download PDF

Info

Publication number
WO2012019053A3
WO2012019053A3 PCT/US2011/046663 US2011046663W WO2012019053A3 WO 2012019053 A3 WO2012019053 A3 WO 2012019053A3 US 2011046663 W US2011046663 W US 2011046663W WO 2012019053 A3 WO2012019053 A3 WO 2012019053A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
methods
hdm2
impairing
auto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/046663
Other languages
French (fr)
Other versions
WO2012019053A2 (en
Inventor
Carlo M. Croce
Flavia Pichiorri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University
Original Assignee
Ohio State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University filed Critical Ohio State University
Priority to US13/813,773 priority Critical patent/US20130150430A1/en
Priority to EP11815348.5A priority patent/EP2600871A2/en
Publication of WO2012019053A2 publication Critical patent/WO2012019053A2/en
Anticipated expiration legal-status Critical
Publication of WO2012019053A3 publication Critical patent/WO2012019053A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods and compositions for detecting, treating, characterizing, and diagnosing multiple myeloma are described.
PCT/US2011/046663 2010-08-04 2011-08-04 Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 Ceased WO2012019053A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/813,773 US20130150430A1 (en) 2010-08-04 2011-08-04 Methods for Impairing the P53/HDM2 Auto-Regulatory Loop in Multiple Myeloma Development Using mIR-192, mIR-194 and mIR-215
EP11815348.5A EP2600871A2 (en) 2010-08-04 2011-08-04 Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37069210P 2010-08-04 2010-08-04
US61/370,692 2010-08-04

Publications (2)

Publication Number Publication Date
WO2012019053A2 WO2012019053A2 (en) 2012-02-09
WO2012019053A3 true WO2012019053A3 (en) 2014-03-20

Family

ID=45560082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046663 Ceased WO2012019053A2 (en) 2010-08-04 2011-08-04 Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215

Country Status (3)

Country Link
US (1) US20130150430A1 (en)
EP (1) EP2600871A2 (en)
WO (1) WO2012019053A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
ES2606146T3 (en) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Methods related to microRNA-21 and repair of disappearance in colorectal cancer
CN103313706A (en) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 controlled release mucoadhesive system
GB2486424A (en) * 2010-12-13 2012-06-20 Univ Sussex Markers for plasma cell disorders
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHODS AND MATERIALS RELATED TO OVARIAN CANCER
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
JP2020503390A (en) 2017-01-09 2020-01-30 オイシン バイオテクノロジーズ， インコーポレイテッド Fusogenic lipid nanoparticles, and methods for making and using the same, for target cell-specific production of therapeutic proteins and for treating diseases, conditions, or disorders associated with target cells
CN112312918A (en) 2018-04-18 2021-02-02 奥依信生物技术公司 Fusogenic lipid nanoparticles and methods of making the same and their use for target cell-specific production of therapeutic proteins and treatment of diseases, conditions or disorders associated with target cells
IL289182B2 (en) 2019-07-04 2024-06-01 Lumus Ltd Image waveguide with symmetric beam multiplication
CN114207354B (en) 2019-09-16 2024-06-21 鲁姆斯有限公司 Image display system with beam multiplication
KR102939032B1 (en) 2019-12-05 2026-03-16 루머스 리미티드 A light-guided optical element employing a complementary coated partial reflector, and a light-guided optical element that reduces light scattering
CN115176190B (en) 2020-05-24 2024-07-09 鲁姆斯有限公司 Composite light guide optical element
JP2024532842A (en) 2021-08-23 2024-09-10 ルーマス リミテッド Method for making a composite light-directing optical element having an embedded coupling reflector - Patents.com
CN118600027B (en) * 2024-06-17 2025-04-18 广东生态工程职业学院 A miRNA related to sperm motility and fertilization rate of parrots and its application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
US20090131356A1 (en) * 2006-09-19 2009-05-21 Asuragen, Inc. miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090209450A1 (en) * 2006-03-20 2009-08-20 The Ohio State University MicroRNA Fingerprints During Human Megakaryocytopoiesis
US20100099200A1 (en) * 2007-03-16 2010-04-22 Covalx Ag Direct mass spectrometric analysis of drug candidates targeting protein complexes
US20100104662A1 (en) * 2007-02-27 2010-04-29 Rosetta Genomics, Ltd Composition and methods for modulating cell proliferation and cell death

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209450A1 (en) * 2006-03-20 2009-08-20 The Ohio State University MicroRNA Fingerprints During Human Megakaryocytopoiesis
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
US20090131356A1 (en) * 2006-09-19 2009-05-21 Asuragen, Inc. miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20100104662A1 (en) * 2007-02-27 2010-04-29 Rosetta Genomics, Ltd Composition and methods for modulating cell proliferation and cell death
US20100099200A1 (en) * 2007-03-16 2010-04-22 Covalx Ag Direct mass spectrometric analysis of drug candidates targeting protein complexes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAUN ET AL.: "p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest.", CANCER RES., vol. 68, 2008, pages 10094 - 10104, XP008138920 *
VASSILEV ET AL.: "In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2.", SCIENCE, vol. 303, 2004, pages 844 - 848, XP002338500 *
ZHAO ET AL.: "p53 Mediates the negative regulation of MDM2 by orphan receptor TR3.", EMBO J., vol. 25, 2006, pages 5703 - 5715, XP055136208 *

Also Published As

Publication number Publication date
EP2600871A2 (en) 2013-06-12
US20130150430A1 (en) 2013-06-13
WO2012019053A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
WO2012019053A3 (en) Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215
IL257330B (en) Preparations, methods and kits for diagnosing lung cancer
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
PH12015501263A1 (en) Compositions comprising anti-cd38 antibodies and lenalidomide
PH12014501108A1 (en) Anti-il-36r antibodies
EP2780465A4 (en) Methods, devices, and kits for obtaining and analyzing cells
GB2522366A (en) Mapping cytosine modifications
PH12014502406B1 (en) Anti-il-23p19 antibodies
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
EP2651209A4 (en) SOYBEANS COMPRISING THE SYHT04R TRANSFORMATION MECHANISM, AND COMPOSITIONS AND METHODS FOR DETECTING SUCH MECHANISM
WO2013177429A3 (en) Extreme pcr
WO2014145958A3 (en) Network-based microbial compositions and methods
EA201290638A1 (en) CONNECTIONS AND METHODS
EP2920293A4 (en) MICROBIAL STRAINS, COMPOSITIONS AND METHODS FOR IMPROVING AVAILABLE PHOSPHATE FOR PLANTS
EP2670419A4 (en) PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREFOR
EP2600761A4 (en) Biosensor membrane composition, biosensor, and methods for making same
WO2012054747A3 (en) Methods and compositions for treating tumors using myeloid derived suppressor cells
IL219827A0 (en) Lyophilization methods, compositions, and kits
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
BR112013012450A2 (en) compositions, detection methods and kits
ZA201307104B (en) Compositions, methods, and kits for detecting and indentifying mycobactetia
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
EP2403865A4 (en) COMPOSITIONS, METHODS AND KITS FOR PREPARING PLASMINOGEN, AND PLASMINE PREPARED THEREFROM
WO2012106680A8 (en) Methods and compositions for chemical drying and producing struvite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815348

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13813773

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011815348

Country of ref document: EP